-+ 0.00%
-+ 0.00%
-+ 0.00%
Telomir Pharma Selects Linical To Support FDA-Cleared Phase 1/2 Clinical Trial Evaluating Telomir-Zn In Patients With Advanced Or Metastatic Triple-Negative Breast Cancer
Share
Listen to the news

Global CRO Brings Extensive Oncology Experience, Including Breast Cancer and Early-Phase Clinical Development

Executed Clinical Trial Agreements Support Targeted Clinical Initiation in the First Quarter of 2027

MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer, today announced that it has selected Linical, a global contract research organization (CRO) with extensive oncology experience, to support its FDA-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC).

Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework to advance the study toward clinical initiation, targeted for the first quarter of 2027.

The engagement follows the U.S. Food and Drug Administration's clearance of Telomir's Investigational New Drug (IND) application and represents an important operational milestone as the Company advances toward clinical execution.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending